Clinical trials: Cardiology
Hypertension, Diastolic Dysfunction
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7…
- Trial name
- NCT00523549
- Testing
- valsartan, amlodipine
- Where
- United States
- Volunteers
- 229 people
- Sponsor
- Novartis Pharmaceuticals
Stroke
Non-invasive Brain Stimulation (NIBS) and Dual-task Walking After Stroke
The study aims to identify neural locus critical for dual-task walking (walking and talking) in individuals with stroke. To achieve this aim, the investigators apply repetitive transcranial magnetic stimulation (rTMS) to…
- Trial name
- NCT03442868
- Testing
- high frequency rTMS
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Texas Woman's University
Waldenstrom's Macroglobulinemia
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM.
- Trial name
- NCT00492050
- Testing
- Bortezomib, Rituximab, Valacyclovir
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Sudden Cardiac Death
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of…
- Trial name
- APPRAISE ATP (NCT02923726)
- Testing
- Arm 1 (ATP+Shock), Arm 2 (shock only)
- Where
- 134 sites in United States, Austria and 6 more
- Volunteers
- 2,692 people
- Sponsor
- Boston Scientific Corporation
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study.
- Trial name
- ALLEVIATE-HF (NCT04452149)
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention, Not Randomized to Device or Medication Intervention
- Where
- 53 sites in United States
- Volunteers
- 826 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease (CAD)
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
After a stent procedure, it is common practice to prescribe anti-platelet medication to prevent the blood from clotting. The main objective of this study is to determine if there is a better medication strategy to prevent blood…
- Trial name
- NCT01813435
- Testing
- Ticagrelor, Acetylsalicylic Acid, Clopidogrel
- Where
- 130 sites in Australia, Austria and 16 more
- Volunteers
- 15,991 people
- Sponsor
- ECRI bv
Traumatic Brain Injury
Prehospital Tranexamic Acid Use for Traumatic Brain Injury
Primary aim: To determine the efficacy of two dosing regimens of TXA initiated in the prehospital setting in patients with moderate to severe TBI (GCS score ≤12).
- Trial name
- TXA (NCT01990768)
- Testing
- 1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable
- Where
- 12 sites in United States, Canada
- Volunteers
- 967 people
- Sponsor
- University of Washington
Stroke
Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment
People with post-stroke aphasia are left with some degree of chronic deficit for which current rehabilitative treatments are variably effective.
- Trial name
- NCT02901574
- Testing
- Anodal or Cathodal tDCS, Computerized naming therapy
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Johns Hopkins University
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
Subarachnoid Hemorrhage
FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension
The objective of this study is to further demonstrate safety and characterize effectiveness of the Neurapheresis™ System (extracorporeal system and catheter) to remove red blood cells (RBCs) and lysed blood by-products from…
- Trial name
- PILLAR-XT (NCT03607825)
- Testing
- Neurapheresis System
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Minnetronix
Heart Failure
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease.
- Trial name
- NCT01598740
- Testing
- CLP, Spironolactone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sorbent Therapeutics
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atrial Fibrillation, Atrial Fibrillation Recurrent
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
Patients who have undergone cardiac ablation will be randomized and blinded to one of two groups; one group will receive dronedarone while the other group will receive a placebo.
- Trial name
- EDORA (NCT04704050)
- Testing
- dronedarone 400 mg Oral Tablet
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tulane University School of Medicine
Waldenstrom's Macroglobulinemia
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
The purpose of this study is to find out if the combination of bortezomib (Velcade), dexamethasone (Decadron) and rituximab (Rituxan) is effective in treating Waldenstrom's macroglobulinemia.
- Trial name
- NCT00250926
- Testing
- Bortezomib, Dexamethasone, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Subdural Hematoma
Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma
Chronic subdural hematoma (cSDH) is condition where blood has slowly leaked out of small blood vessels surrounding the brain. Over time, the blood may cause a variety of symptoms including headache, confusion, limb weakness, and…
- Trial name
- DECS (NCT02111785)
- Testing
- Dexamethasone, Burr Hole Craniostomy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Virginia
Tissue Donors, Liver Transplantation
The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy
Liver transplantation is the gold standard treatment for patients with end-stage liver disease. Despite its outstanding success, liver transplantation still entails certain complications including ischemia-reperfusion injury.
- Conditions
- Tissue Donors, Liver Transplantation, Ischemia Reperfusion Injury
- Trial name
- NCT03386435
- Testing
- remote ischemic preconditioning
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Asan Medical Center
Heart Failure
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Heart failure is a disorder in which the heart does not pump blood adequately. This can lead to several serious problems, including reduced blood flow throughout the body, congestion of blood in the veins and lungs, and fluid…
- Trial name
- NCT00577135
- Testing
- Furosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification
- Where
- 9 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- Duke University
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to…
- Trial name
- STRENGTH (NCT02104817)
- Testing
- Epanova® (omega-3 carboxylic acids), corn oil control
- Where
- 684 sites in United States, Australia and 20 more
- Volunteers
- 13,078 people
- Sponsor
- AstraZeneca
Hypertension
The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)
This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in…
- Trial name
- NCT01130168
- Testing
- Comparator: Amlodipine, Comparator: ISMN ER
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of this research study is to determine the safety of plerixafor and bortezomib, and the highest dose that can be given to people safely.
- Trial name
- NCT00903968
- Testing
- Plerixafor, bortezomib, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.